1312309-63-9 Usage
Description
Azido-PEG2-acid is a PEG (polyethylene glycol) linker that features an azide group and a terminal carboxylic acid. This molecule is designed to enhance solubility in aqueous environments due to the hydrophilic nature of the PEG spacer. The azide group within the molecule is capable of undergoing Click Chemistry reactions with alkyne, BCN, and DBCO, resulting in the formation of a stable triazole linkage. Additionally, the terminal carboxylic acid can react with primary amine groups in the presence of activators such as EDC or HATU, leading to the formation of a stable amide bond.
Uses
Used in Bioconjugation:
Azido-PEG2-acid is used as a bioconjugation agent for the formation of stable amide bonds with primary amine groups. The application reason is to facilitate the attachment of various biomolecules, such as proteins or peptides, to the PEG linker, enhancing their stability and solubility in aqueous media.
Used in Drug Delivery Systems:
Azido-PEG2-acid is used as a component in drug delivery systems for the development of targeted therapies. The application reason is to improve the solubility and bioavailability of drugs, as well as to enable site-specific drug delivery through the use of Click Chemistry to attach targeting ligands to the drug carrier.
Used in Materials Science:
Azido-PEG2-acid is used as a building block in the synthesis of functional materials for various applications. The application reason is to incorporate the PEG spacer and reactive azide group into the material's structure, allowing for the subsequent attachment of other molecules or the formation of complex architectures through Click Chemistry.
Used in Chemical Synthesis:
Azido-PEG2-acid is used as an intermediate in the synthesis of more complex molecules. The application reason is to provide a versatile platform for further chemical modifications, taking advantage of the reactivity of both the azide group and the terminal carboxylic acid.
Check Digit Verification of cas no
The CAS Registry Mumber 1312309-63-9 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,1,2,3,0 and 9 respectively; the second part has 2 digits, 6 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 1312309-63:
(9*1)+(8*3)+(7*1)+(6*2)+(5*3)+(4*0)+(3*9)+(2*6)+(1*3)=109
109 % 10 = 9
So 1312309-63-9 is a valid CAS Registry Number.
1312309-63-9Relevant articles and documents
Synthesis of nucleobase-functionalized carbon nanotubes and their hybridization with single-stranded DNA
Hwu, Jih Ru,Kapoor, Mohit,Li, Rou-Ying,Lin, Yung-Chieh,Horng, Jia-Cherng,Tsay, Shwu-Chen
, p. 3408 - 3412 (2014)
For the first time ssDNA (25-aptamer of mixed dA, dT, dG, and dC) was wrapped around functionalized single-walled carbon nanotubes (SWCNTs), whose external surfaces were attached to multiple triazole-(ethylene glycol)-dA ligands. This method of hybridization involved the formation of hydrogen bonds between dT of ssDNA and dA of functionalized SWCNTs. It deviates from the reported π-π stacking between the nucleobases of DNA and the external sidewalls of nanotubes. The structural properties of the functionalized SWCNTs and its ssDNA complex were characterized by spectroscopic (including CD and Raman), thermogravimetric, and microscopic (TEM) methods. The results thus obtained establish a new platform of DNA delivery by use of nanotubes as a new vehicle with great potential in biomedical applications and drug development.
Synthesis of KUE-siRNA Conjugates for Prostate Cancer Cell-Targeted Gene Silencing
Yang, Chao,Ma, Dejun,Lu, Liqing,Yang, Xing,Xi, Zhen
, p. 2888 - 2895 (2021/08/03)
The delivery of siRNAs to selectively target cells poses a great challenge in RNAi-based cancer therapy. The lack of suitable cell-targeting methods seriously restricts the advance in delivering siRNAs to extrahepatic tissues. Based on prostate-specific m
CROSS-LINKED PYRROLOBENZODIAZEPINE DIMER (PBD) DERIVATIVE AND ITS CONJUGATES
-
, (2020/01/31)
A novel cross-linked cytotoxic agents, pyrrolobenzo-diazepine dimer (PBD) derivatives, and their conjugates to a cell-binding molecule, a method for preparation of the conjugates and the therapeutic use of the conjugates.
